Bliss GVS Pharma Ltd. has achieved a significant financial turnaround in Q4, reporting a consolidated net profit of 155.4 crore rupees compared to a 91.5 crore rupees loss in the same quarter last year. Revenue remained stable at 198.00 crore rupees year-over-year. The company's sequential growth shows profit increased from 23.80 crore rupees in the previous quarter. Despite stable revenue, Bliss GVS Pharma demonstrated improved operational efficiency with decreased interest costs, indicating better debt management.
Bliss GVS Pharma posted a consolidated net profit of ₹155.40 crore in Q4, reversing a loss of ₹91.50 crore from the previous year. Revenue remained stable at ₹1,980.00 crore. However, EBITDA decreased to ₹210.90 crore from ₹283.50 crore year-over-year, with EBITDA margin contracting to 10.65% from 14.31%. The results indicate a mixed performance with profit improvement but ongoing operational challenges.
15Apr 25
Bliss GVS Pharma's U.S. Partner Secures FDA Approval for Mesalamine Suppositories
Bliss GVS Pharma's U.S. partner, Rising Pharma Holdings, received FDA approval for Mesalamine Suppositories 1000 mg. The product targets a $29 million U.S. market. This approval strengthens Bliss GVS Pharma's portfolio of differentiated products for the U.S. market and demonstrates their in-house R&D capabilities.